Correlation Between COVID-19 and Radiation Pneumonitis in Breast Cancer

NCT07188116 | Not Yet Recruiting

• 1 other identifier: COBRA-001
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

This study was designed as a single-center retrospective analysis aimed at investigating whether COVID-19 infection increases the risk or burden of radiation-induced pneumonitis in breast cancer patients.

Conditions

Breast Cancer; Radiation Pneumonia; COVID-19

Keywords

Retrospective Analysis; COVID-19; Radiation Pneumonitis; Propensity Score Matching; Breast Cancer

Outcome Measures

Primary Outcomes (1)

• Radiation Pneumonitis Situation

  The incidence rate, severity and onset time of radiation pneumonitis

  From January 2021 to June 2024

Study Arms (2)

Without COVID-19

No COVID-19 infection

Other: COVID-19

With COVID-19

With COVID-19 infection

Other: COVID-19

Interventions

COVID-19 OTHER

The COVID-19 infection situation was used as an intervention measure, and the cohort was divided into groups.

With COVID-19; Without COVID-19

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Breast cancer patients who underwent radiotherapy at the Cancer Center of Zhejiang Hospital between January 1, 2021, and June 30, 2024, were screened for eligibility.

You may qualify if:

• patients with pathologically or cytologically confirmed primary breast cancer,
• aged 18 years or older but younger than 80 years,
• with complete and reliable medical records,
• for those with COVID-19 infection, documented evidence of a positive test result.

You may not qualify if:

• concomitant pulmonary malignancies,
• a history of prior thoracic radiotherapy,
• concurrent pulmonary infections other than COVID-19 during radiotherapy,
• missing key data with loss to follow-up,
• or any other condition considered unsuitable for enrollment by the investigators.

Sponsors & Collaborators

• Zhejiang Hospital: lead

Study Sites (1)

Zhejiang Hospital, Department of Oncology, Hangzhou, China, 310030

Hangzhou, Zhejiang, 310030, China

Location

MeSH Terms

Conditions

Breast Neoplasms; Radiation Pneumonitis; COVID-19

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Lung Diseases, Interstitial; Lung Diseases; Respiratory Tract Diseases; Lung Injury; Radiation Injuries; Wounds and Injuries; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections

Central Study Contacts

Pengyuan Liu

CONTACT

18368846455; oncologyliupengyuan@outlook.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 22, 2025
• First Posted: September 23, 2025
• Study Start: September 15, 2025
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: September 23, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)